The development of periodontal and endodontal tissue regenetation targeted amelogenin/GRP78 complex

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K09958
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 57030:Conservative dentistry-related
• Research Institution: Kyushu University
• Principal Investigator: Sanui Terukazu 九州大学, 大学病院, 講師 (70507780)
• Co-Investigator(Kenkyū-buntansha): 福田 隆男 九州大学, 大学病院, 講師 (80507781) ; 武富 孝治 久留米大学, 医学部, 准教授 (10553290)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: アメロジェニン / テプレノン / GRP78 / 血管新生 / 創傷治癒

Outline of Final Research Achievements

We observed that teprenone (GGA) treatment increased Grp78 protein expression in hPDLCs and enhanced cell migration. Microarray analysis demonstrated that increased Grp78 expression triggered the production of Angptl4 and amphiregulin, which are involved in the enhancement of angiogenesis and subsequent wound healing. Moreover, the addition of recombinant murine amelogenin (rM180) further accelerated hPDLC migration and tube formation of human umbilical vein endothelial cells due to the upregulation of IL-8, MCP-1, and IL-6, which are also known as angiogenesis-inducing factors. These findings suggest that the application of GGA to gingival tissue and alveolar bone damaged by periodontal disease would facilitate the wound healing process by inducing periodontal ligament cells to migrate to the root surface and release cytokines involved in tissue repair.

Free Research Field

歯周病学

Academic Significance and Societal Importance of the Research Achievements

本研究によりテプレノン（GGA）・アメロジェニンによる組織再生のメカニズムが証明されたため、将来的に安価かつ安全な歯周・歯髄組織再生薬によって医療福祉政策に大きく貢献する可能性が示唆される。さらに、免疫抑制剤や治癒促進剤等として医科領域まで適応範囲を拡げることができれば、医療費の抑制にも繋がるかもしれない。